Clinical Trials Directory

Trials / Unknown

UnknownNCT04818918

Coronary Flow and Myocardial Viability: the FloVITA Study

Study of the Relationship Between Coronary Flow and Myocardial Viability: the Single-centre, Observational, Prospective FloVITA Study

Status
Unknown
Phase
Study type
Observational
Enrollment
45 (estimated)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value \>0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass. Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI. In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.

Conditions

Interventions

TypeNameDescription
DEVICEAbsolute coronary flow measurementAbsolute coronary flow will be measured.
DEVICEMicrovascular resistance measurementMicrovascular resistance will be measured.
OTHERCardiac MRICardiac MRI will be performed to evaluate myocardial viability.

Timeline

Start date
2021-05-19
Primary completion
2024-08-20
Completion
2024-08-20
First posted
2021-03-26
Last updated
2024-02-01

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04818918. Inclusion in this directory is not an endorsement.